Aradhana Sarin, CFO of AstraZeneca (AZN), talks about the company's recent earnings and the "most positive than negative" trials in drugs it hopes to bring to healthcare markets. She adds that R&D productivity "is starting to kick in" and will offer leverage for AstraZeneca's next stage of growth.